Application of natural quinone compounds in preparing anti-plant virus agents and plant virus agents

By developing anti-plant virus agents containing natural quinone compounds, the problem of difficult to effectively prevent and control plant viruses in the existing technology has been solved, and the significant prevention and control effect on a variety of plant viruses has been achieved, and environmentally friendly and economical characteristics have been achieved.

CN116548443BActive Publication Date: 2024-11-05NORTHWEST A & F UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310313567.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-28
Publication Date
2024-11-05
Estimated Expiration
2043-03-28

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and control plant viruses, especially because plant viruses parasitize in plant cells, inhibit virus activity without destroying host function, and prevention and control measures are affected by external factors, resulting in prevention and control difficulties.

Method used

Develop anti-plant virus agents prepared with natural quinone compounds, using madderin, madder lactone, 2-methyl-1-hydroxyanthraquinone, 2-methyl-1,4-dihydroxyanthraquinone, 1, 3-dihydroxyanthraquinone and/or 1,3,6-trihydroxy-2-methylanthraquinone are used as raw materials to make high-efficiency, pollution-free and low-priced plant-source anti-plant virus agents suitable for tobacco, chili, Prevention and control of crops such as tomatoes.

Benefits of technology

This antiviral agent is significantly effective against a variety of plant virus diseases, such as tobacco mosaic virus, cucumber mosaic virus and potato virus disease, has good prevention and control effects, good environmental compatibility, no residual poisoning of biological pesticides, abundant resources and preparation Simple and low-cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004149379710000071
    Figure BDA0004149379710000071
  • Figure BDA0004149379710000072
    Figure BDA0004149379710000072
  • Figure BDA0004149379710000081
    Figure BDA0004149379710000081
Patent Text Reader

Abstract

The invention discloses an application of preparing an anti-plant virus agent containing natural quinone compounds and a plant virus agent, wherein the natural quinone compounds are macrophylla rubiacein, rubia lactone, 2-methyl-1-hydroxyanthraquinone, 2-methyl-1,4-dihydroxyanthraquinone, 1,3-dihydroxyanthraquinone and / or 1,3,6-trihydroxy-2-methylanthraquinone, and are prepared into a soluble solution, an aqueous solution and a microemulsion with auxiliary agents. It can be used to prevent and treat various plant virus diseases such as tobacco mosaic virus (Tobacco mosaic virus, TMV), cucumber mosaic virus (Cucumber mosaic virus, CMV) and potato virus disease (Potato Virus X, PVX; Potato Virus Y, PVY) on crops such as tobacco, pepper, tomato, zucchini, and potato. The anti-plant virus agent of the present invention not only has a good antiviral effect, but also is safe for the environment, humans, livestock, natural enemies of pests and other beneficial organisms. The preparation process of the anti-plant virus agent is simple, the cost is low, and it is suitable for promotion and application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of plants and their applications, and specifically relates to the application of natural quinone compounds in preparing anti-plant virus agents and plant virus agents. Background Art

[0002] Plant viruses are intracellular parasitic pathogens composed of nucleic acids and proteins with infectious activity. According to the eighth report of the International Committee on Taxonomy of Viruses (ICTV), there are currently 1,122 species of plant viruses discovered worldwide. Plant diseases caused by plant viruses are known as "plant cancers". Their degree of harm to crops is second only to fungal pathogens. Almost every crop is harmed by 2 to 3 viruses. The world's losses caused by plant viruses are about 40 billion US dollars each year, and the damage caused by tobacco mosaic virus (TMV) alone exceeds 100 million US dollars.

[0003] Plant viruses parasitize in plant cells and complete their own replication and proliferation by "hijacking" the host cell metabolism. Therefore, it is quite difficult to inhibit viral activity without destroying the host's own functions. At the same time, affected by external factors such as climate, changes in industrial structure, and international trade, the occurrence patterns of plant viruses continue to change, making the prevention and control of plant viruses more difficult. At present, the main means of prevention and control of plant viruses include breeding resistant varieties, controlling the spread of viruses in vectors, and chemical means. In recent years, people have successively discovered that many natural small molecules from plants have anti-plant virus activity, and plant-based antiviral agents have also attracted more and more attention from scholars at home and abroad, which provides new ideas and directions for the research of anti-plant virus agents.

[0004] Rubia cordifolia L., also known as blood madder, blood-seeing sorrow, ground sumac, and blood-activating dan, is a perennial herbaceous climbing vine of the Rubiaceae family. It often grows in sparse forests, forest edges, shrubs or grasslands. It is widely distributed in Northeast my country, North China, Northwest China, Sichuan and Tibet, and is also distributed in North Korea, Japan and the Russian Far East. The main components of Rubia cordifolia are small molecule compounds such as anthraquinone and naphthoquinone, and others include peptides and polysaccharides. Rubia cordifolia is one of the earliest plants used by people. It has a long history as a red dye. It is also one of the commonly used traditional Chinese medicines in my country. It has the effects of cooling blood and stopping bleeding, promoting blood circulation and removing blood stasis, treating injuries and rheumatism. With the gradual deepening of research on the components of Rubia cordifolia, the pharmacological activity of Rubia cordifolia has been further clarified, such as in vitro antibacterial, analgesic and anti-inflammatory, anti-cancer, antitussive and expectorant effects. In agriculture, the activity of madder is mainly reflected in its control effects on Lepidoptera pests and Hemiptera pests including aphids, cotton bollworms and diamondback moths. So far, no research has been found on the anti-plant virus related aspects of madder.

[0005] Mollugin, 6-hydroxy-2,2-dimethylbenzo[h]benzopyran-5-carboxylic acid methyl ester, is a quinone compound, light yellow needle-shaped crystals, soluble in organic solvents such as methanol, ethanol, DMSO, slightly soluble in water, with a molecular formula of C 17 H 16 O4, with a molecular weight of 284.31, is a natural ingredient from Rubia cordifolia L., a plant of the Rubiaceae family. Studies have shown that rubia cordifolia can significantly improve the pathological state of NAFLD induced by high fat in mice, inhibit the proliferation and migration of lung cancer A549 and H1299 cells, and inhibit Mycobacterium tuberculosis H37Rv. It also has a wide range of biological activities in cooling blood and stopping bleeding, anti-cancer, antibacterial, antioxidant, and anti-tumor. In agriculture, rubia cordifolia has antifeedant and contact killing effects on lepidopteran pests such as cotton bollworms. It has great utilization value and broad market prospects. It has become one of the hot natural active ingredients in recent years. At present, no research has been found on the anti-plant virus effect of rubia cordifolia.

[0006] Rubilactone, 3'-methoxycarbonyl-4'-hydroxy-naphtho[1',2'-2,3]pyran-6-one, quinone compound, light yellow needle-shaped crystals, soluble in organic solvents such as methanol, ethanol, ethyl acetate, DMSO, slightly soluble in water, molecular formula is C 15 H 10 O5, molecular weight is 270.24; 2-methyl-1-hydroxyanthraquinone (1-Hydroxy-2-methylanthraquinone), molecular formula is C 15 H 10 O3, molecular weight 238.24, quinone compound, soluble in organic solvents such as methanol, ethanol, ethyl acetate, DMSO, slightly soluble in water; 2-Methyl-1,4-dihydroxyanthraquinone (2-Methyl-1,4-dihydroxyanthraquinone), molecular formula C 15 H 10 O4, molecular weight is 254.24, quinone compound, soluble in methanol, ethanol, ethyl acetate, DMSO and other organic solvents, slightly soluble in water; 1,3-dihydroxyanthraquinone (1,3-Dihydroxyanthraquinone), molecular formula is C 14 H8O4, molecular weight is 240.211, quinone compound, soluble in methanol, ethanol, ethyl acetate, DMSO and other organic solvents, slightly soluble in water; 1,3,6-Trihydroxy-2-methylanthraquinone, (1,3,6-Trihydroxy-2-methylanthraquinone), molecular formula is from C 15 H 10O5, molecular weight is 270.24, quinone compound, soluble in organic solvents such as methanol, ethanol, ethyl acetate, DMSO, slightly soluble in water.

[0007] Six compounds including rubiacin and other rubia lactones are natural quinone compounds from Rubia cordifolia L., a plant of the Rubiaceae family. Currently, there are few studies on these compounds, most of which are in the fields of medical antibacterial and anti-inflammatory activity and pharmaceutical chemistry, and no research reports on their anti-plant virus effects have been found. Summary of the invention

[0008] The purpose of the present invention is to provide an application of natural quinone compounds in preparing anti-plant virus agents and plant virus agents, and to develop a highly efficient, pollution-free and low-cost plant-derived anti-plant virus agent using madderol, madder lactone, 2-methyl-1-hydroxyanthraquinone, 2-methyl-1,4-dihydroxyanthraquinone, 1,3-dihydroxyanthraquinone and / or 1,3,6-trihydroxy-2-methylanthraquinone as raw materials.

[0009] To achieve the above object, the present invention adopts the following technical solutions:

[0010] The invention discloses an application of natural quinone compounds in preparing anti-plant virus agents, wherein the compounds include madderol, madder lactone, 2-methyl-1-hydroxyanthraquinone, 2-methyl-1,4-dihydroxyanthraquinone, 1,3-dihydroxyanthraquinone and / or 1,3,6-trihydroxy-2-methylanthraquinone.

[0011] Optionally, the mass percentage of the natural quinone compounds in the anti-plant virus agent is 1% to 5%.

[0012] Optionally, the mass percentage of the natural quinone compounds in the anti-plant virus agent is 4%.

[0013] Optionally, the anti-plant virus agent is a microemulsion, a soluble liquid or an aqueous solution.

[0014] Optionally, the microemulsion is prepared from the following raw materials in weight percentage: 1% to 5% natural quinone compounds, 0% to 50% organic solvents, 5% to 30% surfactants, 5% to 10% antifreeze, and the remainder is water. The sum of the weight percentages of the raw materials is 100%; the endpoint value of 0 is not included.

[0015] Optionally, the soluble liquid is prepared from the following raw materials in weight percentage: 1% to 5% natural quinone compounds, 0% to 70% organic solvents, and 5% to 30% surfactants, and the sum of the weight percentages of the raw materials is 100%; the endpoint value of 0 is not included.

[0016] Optionally, the aqueous solution is prepared from the following raw materials in weight percentage: 1% to 5% natural quinone compounds, 0% to 50% organic solvents, 5% to 30% surfactants, 5% to 10% antifreeze, and the remainder is water. The sum of the weight percentages of the raw materials is 100%; the endpoint value of 0 is not included.

[0017] The invention discloses an anti-plant virus agent, which is mainly composed of natural quinone compounds and added with auxiliary agents, and the preparation form is microemulsion, soluble liquid or aqueous solution.

[0018] Optionally, the mass percentage of the natural quinone compounds in the anti-plant virus agent is 1% to 5%.

[0019] Optionally, the mass percentage of the natural quinone compounds in the anti-plant virus agent is 4%.

[0020] The anti-plant virus agent prepared by the present invention has the following advantages:

[0021] The natural quinone compound provided by the invention has significant anti-plant virus activity and can be used for preventing and controlling tobacco mosaic virus (TMV), cucumber mosaic virus (CMV) and potato virus (PVX; PVY) and other plant virus diseases on crops such as tobacco, pepper, tomato, zucchini and potato. The compound is safe to humans, livestock, natural enemies of pests and other beneficial organisms and has good environmental compatibility. The compound is a biogenic pesticide and has no residual toxicity after use. The compound is rich in resources, simple in preparation method, low in cost and suitable for popularization and use. DETAILED DESCRIPTION

[0022] The scheme of the present invention is described in detail below through specific embodiments.

[0023] The present invention has discovered the use of natural quinone compounds in preparing anti-plant virus agents, which specifically include: the anti-plant virus agent of the present invention is mainly composed of the effective ingredients of madder extract, madder lactone, 2-methyl-1-hydroxyanthraquinone, 2-methyl-1,4-dihydroxyanthraquinone, 1,3-dihydroxyanthraquinone and / or 1,3,6-trihydroxy-2-methylanthraquinone, and is made into a soluble liquid, aqueous solution or microemulsion through a certain processing process; (excluding the endpoint value of %0) wherein:

[0024] The microemulsion is prepared from the following raw materials in percentage by weight: 1% to 5% of active ingredient, 0% to 50% of organic solvent, 5% to 30% of surfactant, 5% to 10% of antifreeze agent, and the balance is water, and the sum of the percentage by weight of the raw materials is 100%;

[0025] The soluble liquid is prepared from the following raw materials in percentage by weight: 1% to 5% of active ingredient, 0% to 70% of organic solvent, 5% to 30% of surfactant, and the sum of the percentage by weight of the raw materials is 100%;

[0026] The aqueous solution is prepared from the following raw materials in percentage by weight: 1% to 5% of active ingredient, 0% to 50% of organic solvent, 5% to 30% of surfactant, 5% to 10% of antifreeze agent, and the balance is water, and the sum of the percentage by weight of the raw materials is 100%;

[0027] The organic solvent in the present invention is selected from at least one of ethyl acetate, sec-butyl acetate, cyclohexanone, methyl oleate, ethanol, methanol, solvent oil 120#, solvent oil 150# and solvent oil 200#;

[0028] The emulsifier in the present invention is at least one selected from alkylbenzene sulfonates, alkylphenol polyoxyethylene ethers, phenethylphenol polyoxyethylene ethers, phenethylphenol polyoxyethylene ether polyoxypropylene ethers and the like, span series and tween;

[0029] The surfactant in the present invention is at least one selected from alkylbenzene sulfonates, alkylphenol polyoxyethylene ethers, phenethylphenol polyoxyethylene ethers, phenethylphenol polyoxyethylene ethers and similar substances, adducts of castor oil and ethylene oxide, and arylalkylphenol polyoxyethylene ether formaldehyde condensates;

[0030] The synergist in the present invention is selected from at least one of silicone, synergistic ether, synergistic amine, alkyl carbonate and laurocapram;

[0031] The antifreeze agent in the present invention is ethylene glycol or propylene glycol;

[0032] The thickener in the present invention is at least one of polyvinyl alcohol, xanthan gum, sodium carboxymethyl cellulose and magnesium aluminum silicate.

[0033] The plant-derived antiviral agent of the present invention is mainly composed of rubiacein, rubia lactone, 2-methyl-1-hydroxyanthraquinone, 2-methyl-1,4-dihydroxyanthraquinone, 1,3-dihydroxyanthraquinone and / or 1,3,6-trihydroxy-2-methylanthraquinone, and a certain proportion of auxiliary agents are added for dosage form processing, so that an environmentally friendly preparation microemulsion, aqueous solution or soluble liquid can be prepared; the inventor's experiments have proved that the anti-plant virus agent has a good control effect on tobacco mosaic virus (TMV).

[0034] Among them, the applicant conducted phytochemical separation on Rubia cordifolia L., and obtained a total of 6 compounds Q1 to Q6 from the petroleum ether extraction section of 95% ethanol extract of Rubia cordifolia, namely, rubiacin, rubia lactone, 2-methyl-1-hydroxyanthraquinone, 2-methyl-1,4-dihydroxyanthraquinone, 1,3-dihydroxyanthraquinone and 1,3,6-trihydroxy-2-methylanthraquinone. The separation and identification process is as follows;

[0035] The petroleum ether segment was separated by silica gel column chromatography, the elution system was petroleum ether: ethyl acetate, and the specific ratios of gradient elution were petroleum ether: ethyl acetate (V / V) 1:0, 200:1, 100:1, 50:1, 25:1, 10:1, 5:1, 3:1, 1:1, 0:1. Finally, the column was flushed with pure methanol, and each ratio was flushed for about 4 column volumes, and each column volume was about 3.6 L. After elution by silica gel column chromatography and thin layer chromatography, 15 components were obtained after merging. After activity tracking, the active ingredients of 6 components, namely component 2, component 3, component 7, component 8, component 10, and component 11, were further separated.

[0036] Separation of compound Q1: Component 2 was subjected to silica gel column chromatography. The elution system was petroleum ether: ethyl acetate. The specific elution ratios were petroleum ether: ethyl acetate (V / V) of 1:0, 50:1, 25:1, 10:1, 5:1, 3:1, 1:1, 0:1, to obtain 5 fractions 2-1 to 2-5; fractions 2-1 and 2-2 were further subjected to silica gel column chromatography. After the crystals were taken out and purified, 5.562 g of compound Q1 was obtained.

[0037] Structural identification of compound Q1: pale yellow flaky crystals, mp 128~130℃, EI-MS m / z: 284[M] +. HNMR (CDCl3, 400MHz): δ12.18 (1H, s, OH), δ8.37 (1H, dd, J=8.2, 0.2Hz, H-7), δ8.15 (1H, d, J=8.0Hz, H-10), δ7.610 (1H, d, J=1.2H z, H-9), δ7.51 (1H, s, H-8), δ7.10 (1H, d, J=10.0Hz, H-4), δ5.66 (1H, d, J=10.0Hz, H-3), δ3.99 (3H, s, OMe), δ1.486 (6H, s, CMe2). 13C NMR (CDCl3, 400MHz): 74.65s (C=O), 156.52s (C-6), 141.58s (C-11), 129.35s (C-9), 129.02s (C-10a), 128.84s (C-3), 126.30s (C-8), 125. 08s(C-6a), 124.04s(C-7), 122.34s(C-4), 121.94s(C-10), 112.59s(C-4a), 102.22s(C-5), 74.65s(C-2), 52.31s(OMe), 26.87s(2C, Me2). The above spectral data are consistent with the reported Mollugin in the literature (Yang Minli et al. 2010), so it is speculated that the structure of the compound is Mollugin.

[0038] Separation of compounds Q2 and Q3: Component 3 was subjected to silica gel column chromatography to obtain 4 fractions, namely 3-1 to 3-4, with an elution system of petroleum ether: dichloromethane, and the specific elution ratios of petroleum ether: dichloromethane (V / V) were 1:0, 20:1, 10:1, 5:1, 1:1, and 0:1; fraction 3-3 was then subjected to silica gel column chromatography to obtain 3 fractions, namely 3-3-1 to 3-3-3, and fraction 3-3-2 was passed through a sephadex LH-20 gel column with an elution system of dichloromethane: methanol 1:1. The eluted components were then scraped off the corresponding bands by preparative TLC, with a ratio of petroleum ether: dichloromethane (V / V) of 10:1, to obtain 38.7 mg of compound Q2 and 7.9 mg of compound Q3.

[0039] Structural identification of compound Q2: yellow crystals, EI-MS (m / e) 238 [M] +. 1H-NMR (CDCl 3, 400MHz): δ12.95(OH),8.32-8.27(m,2H,H-5and H-8),7.80-7.78(m,2H,H-6and H-7),7.75(d,1H,H-3or H-4,J=7.6Hz),7.52(d,1H,H-3or H-4, J=7.6Hz), 2.38 (s, 3H, CH 3); 13C-NMR (125MHz, CDCl 3):δ189.14(CO),182.55(CO),161.25(C-1),137.4(d),135.13(s),134.68(d),134.11(d),134.00(s),133.48(s),131.53(s),127.46(d),127.02(d),119.39(d),115.43(s),16.28(CH 3,q). The above spectral data are consistent with the 1-hydroxy-2-methylanthraquinone reported in the literature (Itokawa, H et al. 1983), so it is speculated that the structure of the compound is 1-hydroxy-2-methylanthraquinone.

[0040] Structural identification of compound Q3: red crystal, EI-MS m / z: 254[M] + . 1H-NMR (CDCl3, 400MHz) δ: 13.71 (1H, s, 4-OH), 13.62 (l H, s, 1-OH), 8.50~8.51 (2H, m), 7.95~7.97 (2H, m), 7.21 (1H, s), 2.47 (3H, d, J=1.4Hz, CH3). The above spectral data are basically consistent with the data of 1,4-dihydroxy-2-methylanthraquinone reported in the literature (NPMishchenko et al. 2007), so it is inferred that the compound is 1,4-dihydroxy-2-methylanthraquinone.

[0041] Separation of compound Q4: Component 7 was subjected to silica gel column chromatography to obtain 5 fractions, namely 7-1 to 7-5, with the specific elution ratios of petroleum ether: ethyl acetate (V / V) being 1:0, 20:1, 10:1, 5:1, 1:1, and 0:1; fraction 7-4 was subjected to silica gel column chromatography to obtain 3 fractions, namely 7-4-1 to 7-4-3, with the ratios of petroleum ether: acetone (V / V) being 1:0, 10:1, 5:1, 1:1, and 0:1; the bands were scraped off by preparative TLC and separated by sephadex LH-20 gel column (ratio of dichloromethane: methanol 1:1) to obtain 21.7 mg of compound Q4.

[0042] Structural identification of compound Q4: orange-yellow crystals, ESI-MS m / z: 239[M] - . 1H-NMR (DMSO-d6, 400MHz) δ: 12.71 (1H, s, α-OH), 11.34 (1H, s, β-OH), δ 8.18 (2H, dd, J = 7.2, 2.4Hz, H-5, 8), 7 .92(2H,dt,J=7.2,2.4Hz,H-6,7),7.11(1H,d,J=2.4Hz,H-4),6.67(1H,d,J=2.4Hz,H-2); 13C-NMR(100MHz,D MSO-d6)δ:164.96(C-1),107.95(C-2),165.67(C-3),108.69(C-4),134.92(C-4a),126.56(C-5),134.7(C-6),134.71(C-7),126.56(C-8),133.01(C-8a),186.06(C-9),109.53(C-9a),182.1(C-10),133.14(C-10a). The above spectral data are consistent with the 1,3-dihydroxyanthraquinone (isorubiacin) reported in the literature (Xiao Bingkun et al. 2011), so it is speculated that the structure of the compound is 1,3-dihydroxyanthraquinone (1,3-Dihydroxyanthraquinone).

[0043] Separation of compound Q5: Component 8 was subjected to silica gel column chromatography to obtain 8 fractions, namely 8-1 to 8-8, with the specific elution ratios of petroleum ether: ethyl acetate (V / V) being 1:0, 50:1, 20:1, 10:1, 5:1, 1:1, 0:1; 8-7 was subjected to silica gel column chromatography to obtain 3 fractions, namely 8-7-1 to 8-7-3, and fraction 8-7-3 was purified by sephadex LH-20 gel column chromatography to obtain 32.1 mg of Q5.

[0044] Structural identification of compound Q5: EI-MS m / z: 270[M] +. 1H-NMR (CDCl3, 400MHz) δ: 4.09 (3H, s, OCH3), 6.50 (lH, d, J = 10Hz, H-12), 7.71 (1H, dt, J = 7.6, 7.2Hz, H-7), 7.78(1H,dt,J=7.6,7.2Hz,H-6), 8.45(2H,m,H-5,H-8), 8.74(1H,d,J=10.4Hz,H-11), 12.67(l H,sharp s,1-OH). 13C-NMR (CDCl3, 400MHz) δ: 53.02 (C-14, OMe), 116.09 (C-12), 112.57 (C-3), 122.57 (C-5), 124.29 (C-8), 126.52 (C-9), 129.14 (C-10), 129.43 (C-7), 131.13 (C-6), 146.14 (C-11), 143.17 (C-4), 159.25 (C-13), 160.10 (C-1), 171.78 (C-14, COOH). The above spectral data are consistent with the rubiaceae lactone reported in the literature (Hua Huiming et al. 1992), so it is speculated that the structure of the compound is rubiaceae lactone (rubilactone).

[0045] Separation of compound Q6: Component 10 was subjected to silica gel column chromatography to obtain 6 fractions, namely 10-1 to 10-6, with the specific elution ratios of petroleum ether: ethyl acetate (V / V) being 1:0, 50:1, 20:1, 10:1, 5:1, 1:1, and 0:1; fraction 10-4 was further subjected to silica gel column chromatography to obtain two fractions, 10-4-1 and 10-4-2, with the specific elution ratios of petroleum ether: acetone (V / V) being 1:0, 20:1, 10:1, 5:1, 1:1, and 0:1; 10-4-2 was purified by sephadex LH-20 gel column to obtain 97.3 mg of compound Q6.

[0046] Structural identification of compound Q 6: orange-yellow crystals, EI-MS m / z: 270[M] +. 1H-NMR (CDCl3, 400MHz) δ: 2.53 (3H, S, CH3), 7.22 (1H, S), 8.09 (1H, d, J = 8.6Hz), 7.24 (1H, dd J=8.6Hz, J=2.55Hz), 7.92 (1H, d, J=2.55Hz); 13C-NMR (CDCl3, 400MHz) δ: 163.37 (C-1), 112.76 (C-2), 162.48 (C-3), 107.37(C-4), 135.41(C-4a), 108.83(C-5), 162.43(C-6), 121.61(C-7), 129.70(C-8), 185.98(C-9), 182.32(C-10). The above spectral data are basically consistent with the 1,3,6-trihydroxy-2-methylanthraquinone reported in the literature (Lin Shunquan et al. 2011), so it is speculated that compound 10-4-2-2 is 1,3,6-trihydroxy-2-methylanthraquinone.

[0047] The following are the structures of compounds Q1 to Q6;

[0048]

[0049] The in vitro passivation activity and induction activity of 6 compounds including rubiacein against tobacco mosaic virus were determined by the dead spot method, the concentration was 500μg / mL, and the positive control was 100μg / mL chitosan oligosaccharide. The results are shown in the following table;

[0050] Table 1 Inactivation effect of six compounds on tobacco mosaic virus

[0051]

[0052]

[0053] Note: The concentration of each compound is 500 μg / mL, the concentration of the control agent chitosan oligosaccharide is 100 μg / mL, and the number of dead spots and inhibition rate in the table are the average values ​​of 3 repetitions.

[0054] Table 2 The induction effect of six compounds on tobacco mosaic virus

[0055]

[0056] Note: The concentration of each compound is 500 μg / mL, the concentration of the control agent chitosan oligosaccharide is 100 μg / mL, and the number of dead spots and inhibition rate in the table are the average values ​​of 3 repetitions.

[0057] As shown in Tables 1 and 2 above, the six compounds all had different degrees of in vitro passivation and induction activity against tobacco mosaic virus at a concentration of 500 μg / mL, among which compound Q1 had the best activity, which was equivalent to or better than the positive control chitosan oligosaccharide.

[0058] In order to better understand the essence of the invention, the technical content of the invention is described in detail with examples below, but the invention is not limited to these examples.

[0059] Example 1 Preparation of 5% Rubia cordifolia soluble liquid

[0060] Weigh 5 kg of rubiacein, dissolve it in 30 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzenesulfonate, 5 kg of polyoxyethylene styrene acid ether, and ethanol to make up to 100 kg, mix well, stir at a stirring speed of 800 to 1000 rpm for 10 to 30 minutes, and 100 kg of 5% rubiacein soluble solution can be prepared. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0061] Example 2 Preparation of 4% Rubiacein Microemulsion

[0062] Weigh 4 kg of rubiacein, dissolve it in 50 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzene sulfonate, 6 kg of polyoxyethylene styrene acid ether, and 5 kg of ethylene glycol, mix under high-speed stirring, and heat to about 40°C; add deionized water dropwise under high-speed stirring to make up to 100 kg, and keep the temperature at about 40°C during the process of adding deionized water; after the water is added, heat to 50°C, stir for 1 hour, and prepare 100 kg of 4% rubiacein microemulsion. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0063] Example 3 Preparation of 1% Rubia cordifolia aqueous solution

[0064] Weigh 1 kg of rubiacein, dissolve it in 30 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzene sulfonate, 5 kg of polyoxyethylene styrene acid ether, 5 kg of ethylene glycol, and make up to 100 kg with water, mix well, stir at a stirring speed of 800 to 1000 rpm for 10 to 30 minutes, and 100 kg of 1% rubiacein aqueous solution can be prepared. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0065] Example 4 Preparation of 5% Rubia lactone soluble solution

[0066] Weigh 5 kg of madder lactone, dissolve it in 30 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzene sulfonate, 5 kg of polyoxyethylene styrene acid ether, and ethanol to make up to 100 kg, mix well, stir at a stirring speed of 800 to 1000 rpm for 10 to 30 minutes, and 100 kg of 5% madder lactone soluble solution can be prepared. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0067] Example 5 Preparation of 4% Rubia lactone microemulsion

[0068] Weigh 4 kg of madder lactone, dissolve it in 40 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzene sulfonate, 5 kg of polyoxyethylene styrene acid ether, and 5 kg of glycerol, mix under high-speed stirring, and heat to about 40°C; add deionized water dropwise under high-speed stirring to make up to 100 kg, and keep the temperature at about 40°C during the process of adding deionized water; after the water is added, heat to 50°C, stir for 1 hour, and prepare 100 kg of 4% madder lactone microemulsion. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0069] Example 6 Preparation of 1% Rubia lactone aqueous solution

[0070] Weigh 1 kg of rubiaceae lactone, dissolve it in 20 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzene sulfonate, 5 kg of polyoxyethylene styrene acid ether, 5 kg of glycerol, and make up to 100 kg with water, mix well, and stir at a stirring speed of 800 to 1000 rpm for 10 to 30 minutes to obtain 100 kg of 1% rubiaceae lactone aqueous solution. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0071] Example 7 Preparation of 5% 2-methyl-1-hydroxyanthraquinone soluble liquid

[0072] Weigh 5 kg of 2-methyl-1-hydroxyanthraquinone, dissolve it in 30 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzenesulfonate, 5 kg of polyoxyethylene styrene acid ether, and ethanol to make up to 100 kg, mix well, stir at a stirring speed of 800 to 1000 rpm for 10 to 30 minutes, and 100 kg of 5% 2-methyl-1-hydroxyanthraquinone soluble solution can be prepared. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0073] Example 8 Preparation of 4% 2-methyl-1-hydroxyanthraquinone microemulsion

[0074] Weigh 4 kg of 2-methyl-1-hydroxyanthraquinone, dissolve it in 40 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzene sulfonate, 5 kg of polyoxyethylene styrene acid ether, and 5 kg of glycerol, mix under high-speed stirring, and heat to about 40°C; add deionized water dropwise under high-speed stirring to make up to 100 kg, and keep the temperature at about 40°C during the process of adding deionized water; after the water is added, heat to 50°C, stir for 1 hour, and prepare 100 kg of 4% 2-methyl-1-hydroxyanthraquinone microemulsion. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0075] Example 9 Preparation of 1% 2-methyl-1-hydroxyanthraquinone aqueous solution

[0076] Weigh 1 kg of 2-methyl-1-hydroxyanthraquinone, dissolve it in 20 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzenesulfonate and 5 kg of polyoxyethylene styrene acid ether, make up to 100 kg with water, mix well, stir at a stirring speed of 800 to 1000 rpm for 10 to 30 minutes, and 100 kg of 2-methyl-1-hydroxyanthraquinone 1% aqueous solution can be prepared. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0077] Example 10 Preparation of 5% 2-methyl-1,4-dihydroxyanthraquinone soluble liquid

[0078] Weigh 5 kg of 2-methyl-1,4-dihydroxyanthraquinone, dissolve it in 30 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzenesulfonate, 5 kg of polyoxyethylene styrene acid ether, and ethanol to make up to 100 kg, mix well, stir at a stirring speed of 800-1000 rpm for 10-30 minutes, and 100 kg of 5% 2-methyl-1,4-dihydroxyanthraquinone soluble solution can be obtained. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0079] Example 11 Preparation of 4% 2-methyl-1,4-dihydroxyanthraquinone microemulsion

[0080] Weigh 4kg of 2-methyl-1,4-dihydroxyanthraquinone, dissolve it in 40kg of ethyl acetate, then add 15kg of calcium dodecylbenzenesulfonate, 5kg of polyoxyethylene styrene acid ether, and 5kg of glycerol, mix under high-speed stirring, and heat to about 40°C; add deionized water dropwise to make up to 100kg under high-speed stirring, and keep the temperature at about 40°C during the process of adding deionized water; after the water is added, heat to 50°C, stir for 1 hour, and obtain 100kg of 4% 2-methyl-1,4-dihydroxyanthraquinone microemulsion. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0081] Example 12 Preparation of 1% 2-methyl-1,4-dihydroxyanthraquinone aqueous solution

[0082] Weigh 1 kg of 2-methyl-1,4-dihydroxyanthraquinone, dissolve it in 30 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzenesulfonate, 5 kg of polyoxyethylene styrene acid ether, 5 kg of propylene glycol, and make up to 100 kg with water. After mixing evenly, stir at a stirring speed of 800 to 1000 rpm for 10 to 30 minutes to obtain 100 kg of 1% 2-methyl-1,4-dihydroxyanthraquinone aqueous solution. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0083] Example 13 Preparation of 5% 1,3-dihydroxyanthraquinone soluble liquid

[0084] Weigh 5 kg of 1,3-dihydroxyanthraquinone, dissolve it in 30 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzenesulfonate, 5 kg of polyoxyethylene styrene acid ether, and ethanol to make up to 100 kg, mix well, stir at a stirring speed of 800 to 1000 rpm for 10 to 30 minutes, and 100 kg of 5% 1,3-dihydroxyanthraquinone soluble solution can be obtained. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0085] Example 14 Preparation of 4% 1,3-dihydroxyanthraquinone microemulsion

[0086] Weigh 4kg of 1,3-dihydroxyanthraquinone, dissolve it in 30kg of ethyl acetate, then add 15kg of calcium dodecylbenzene sulfonate, 5kg of polyoxyethylene styrene acid ether, and 5kg of glycerol, mix under high-speed stirring, and heat to about 40°C; add deionized water to make up to 100kg under high-speed stirring, and keep the temperature at about 40°C during the process of adding deionized water; after the water is added, heat to 50°C, stir for 1 hour, and obtain 100kg of 4% 1,3-dihydroxyanthraquinone microemulsion. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0087] Example 15 Preparation of 1% 1,3-dihydroxyanthraquinone aqueous solution

[0088] Weigh 1kg of 1,3-dihydroxyanthraquinone, dissolve it in 30kg of ethyl acetate, then add 15kg of calcium dodecylbenzenesulfonate, 5kg of polyoxyethylene styrene acid ether, 5kg of propylene glycol, and make up to 100kg with water. After mixing evenly, stir at a stirring speed of 800-1000 rpm for 10-30 minutes to obtain 100kg of 1% 1,3-dihydroxyanthraquinone aqueous solution. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0089] Example 16 Preparation of 5% 1,3,6-trihydroxy-2-methylanthraquinone soluble liquid

[0090] Weigh 5 kg of 1,3,6-trihydroxy-2-methylanthraquinone, dissolve it in 30 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzenesulfonate, 5 kg of polyoxyethylene styrene acid ether, and ethanol to make up to 100 kg, mix well, stir at a stirring speed of 800-1000 rpm for 10-30 minutes, and 100 kg of 5% 1,3,6-trihydroxy-2-methylanthraquinone soluble solution can be obtained. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0091] Example 17 Preparation of 4% 1,3,6-trihydroxy-2-methylanthraquinone microemulsion

[0092] Weigh 4 kg of 1,3,6-trihydroxy-2-methylanthraquinone, dissolve it in 40 kg of ethyl acetate, then add 15 kg of calcium dodecylbenzene sulfonate, 5 kg of polyoxyethylene styrene acid ether, and 5 kg of glycerol, mix under high-speed stirring, and heat to about 40°C; add deionized water dropwise under high-speed stirring to make up to 100 kg, and keep the temperature at about 40°C during the process of adding deionized water; after the water is added, heat to 50°C, stir for 1 hour, and obtain 100 kg of 4% 1,3,6-trihydroxy-2-methylanthraquinone microemulsion. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0093] Example 18 Preparation of 1% 1,3,6-trihydroxy-2-methylanthraquinone aqueous solution

[0094] Weigh 1kg of 1,3,6-trihydroxy-2-methylanthraquinone, dissolve it in 20kg of ethyl acetate, then add 15kg of calcium dodecylbenzenesulfonate, 5kg of polyoxyethylene styrene acid ether, 5kg of ethylene glycol, and make up to 100kg with water. After mixing evenly, stir at a stirring speed of 800-1000 rpm for 10-30 minutes to obtain 100kg of 1% 1,3,6-trihydroxy-2-methylanthraquinone aqueous solution. The stability and appearance of the preparation meet the requirements of commercial preparations.

[0095] Example 19 Indoor bioassay of 18 antiviral agents against TMV

[0096] (1) Passivation

[0097] The half-leaf spot method was used for determination. Nicotiana glutinosa, which was in the 5-6 leaf stage and had vigorous growth and consistent growth, was selected as the spot host. The left half leaf was inoculated with a mixture of equal volumes of the drug solution and the virus, and the right half leaf was inoculated with a mixture of equal volumes of distilled water and the virus as a control. The virus inoculation concentration was 10 μg / mL, and the inactivation time was 5 minutes. The surface of the inoculated leaves was immediately rinsed with clean water after inoculation. Four leaves were inoculated for each treatment, and the experiment was repeated 3 times. After 3 days, the number of spots was counted and the inhibition rate was calculated.

[0098] Inhibition rate (%) = (number of control necrosis spots - number of treated necrosis spots) / number of control necrosis spots × 100;

[0099] The test reagents and codes are as follows:

[0100] 5% rubiacein soluble liquid, drug code Y1;

[0101] 4% rubiacein microemulsion, drug code R1;

[0102] 1% Rubia cordifolia aqueous solution, code name S1;

[0103] 5% rubiaceae lactone soluble liquid, drug code Y2;

[0104] 4% madder lactone microemulsion, drug code R2;

[0105] 1% madder lactone aqueous solution, code name S2;

[0106] 5% 2-methyl-1-hydroxyanthraquinone soluble liquid, drug code Y3;

[0107] 4% 2-methyl-1-hydroxyanthraquinone microemulsion, drug code R3;

[0108] 1% 2-methyl-1-hydroxyanthraquinone aqueous solution, code name S3;

[0109] 5% 2-methyl-1,4-dihydroxyanthraquinone soluble liquid, the drug code is Y4; 4% 2-methyl-1,4-dihydroxyanthraquinone microemulsion, the drug code is R4;

[0110] 1% 2-methyl-1,4-dihydroxyanthraquinone aqueous solution, code number S4;

[0111] 5% 1,3-dihydroxyanthraquinone soluble liquid, drug code Y5;

[0112] 4% 1,3-dihydroxyanthraquinone microemulsion, drug code R5;

[0113] 1% 1,3-dihydroxyanthraquinone aqueous solution, code name S5;

[0114] 5% 1,3,6-trihydroxy-2-methylanthraquinone soluble liquid, the drug code is Y6; 4% 1,3,6-trihydroxy-2-methylanthraquinone microemulsion, the drug code is R6; 1% 1,3,6-trihydroxy-2-methylanthraquinone aqueous solution, the drug code is S6;

[0115] The measurement results are shown in Table 3.

[0116] Table 3: Inactivation effects of 18 antiviral agents on TMV in vitro

[0117]

[0118]

[0119] (2) Protective effect against TMV (inhibitory effect on initial TMV infection)

[0120] The half-leaf spot method was used to select 5-6 leaf tobacco plants with the same growth, size and health as the spot hosts. The virus was inoculated 6h, 12h and 24h after the application of the solution. The blank control was treated with clean water. Four leaves were inoculated in each treatment, repeated 3 times, and the number of spots was counted after 3 days to calculate the inhibition rate. The results are shown in Table 4.

[0121] The test reagents and their codes are as in (1).

[0122] Table 4: Inhibitory effects of 18 antiviral agents on TMV primary infection

[0123]

[0124]

[0125]

[0126] (3) Therapeutic effect on TMV (inhibitory effect on TMV proliferation)

[0127] The half-leaf spot method was used to select 5-6 leaf heart-leaf tobacco plants with the same growth, size and health as the spot hosts. The solution was applied 6h, 12h and 24h after virus inoculation. The blank control was water treatment. Four leaves were inoculated in each treatment, repeated 3 times, and the number of spots was counted after 3 days to calculate the inhibition rate. The results are shown in Table 5.

[0128] The test reagents and their codes are as in (1).

[0129] Table 5: The therapeutic effects of 18 antiviral agents on TMV

[0130]

[0131]

[0132]

[0133] As shown in Tables 3, 4 and 5, the 18 plant-derived antiviral agents have good effects on the passivation, protection (anti-infection) and treatment (proliferation inhibition) of TMV, which are all higher than the control agent morpholinoguanidine. copper acetate.

[0134] Example 20 Potted Plant Test of 18 Plant-derived Antiviral Agents against TMV

[0135] (1) Protective effect against ordinary cigarettes

[0136] Selected 5-6 leaf stage, healthy and basically uniform growth common tobacco (Nicotiana tabacum) for testing. The experiment set up two groups: treatment group (i.e., inoculated with TMV after 3 times of application) and control group (inoculated with TMV after 3 times of application of the same amount of water). Spray 200 times diluted solution of 18 kinds of plant-derived antiviral agents and spray 500 times solution of control agent morpholinoguanidine and copper ethyl to treat common tobacco. Apply the medicine once every 5 days, for a total of three times. TMV was inoculated 24 hours after the last application of the medicine, and the inoculation concentration was 1:20 (W / V). The disease situation was checked 14 days and 21 days after inoculation, and the disease index and control effect were calculated. 60 tobacco seedlings were treated for each treatment, and the experiment was repeated 3 times. Calculate the prevention effect.

[0137] Incidence rate = (number of diseased plants in each treatment / total number of plants in the treatment) × 100%;

[0138] Disease index = ∑ (disease level × number of diseased plants) / (highest disease level × total number of plants in each treatment) × 100;

[0139] Disease index growth rate = (disease index after spraying - disease index before spraying) / disease index before spraying × 100%;

[0140] Control effect = (control disease index - treatment disease index) / control disease index × 100%;

[0141] The results of the protective effect assay are shown in Table 6.

[0142] The test reagents and codes are as follows:

[0143] 5% rubiacein soluble liquid, drug code Y1;

[0144] 4% rubiacein microemulsion, drug code R1;

[0145] 1% Rubia cordifolia aqueous solution, code name S1;

[0146] 5% rubiaceae lactone soluble liquid, drug code Y2;

[0147] 4% madder lactone microemulsion, drug code R2;

[0148] 1% madder lactone aqueous solution, code name S2;

[0149] 5% 2-methyl-1-hydroxyanthraquinone soluble liquid, drug code Y3;

[0150] 4% 2-methyl-1-hydroxyanthraquinone microemulsion, drug code R3;

[0151] 1% 2-methyl-1-hydroxyanthraquinone aqueous solution, code name S3;

[0152] 5% 2-methyl-1,4-dihydroxyanthraquinone soluble liquid, drug code Y4;

[0153] 4% 2-methyl-1,4-dihydroxyanthraquinone microemulsion, drug code R4;

[0154] 1% 2-methyl-1,4-dihydroxyanthraquinone aqueous solution, code number S4;

[0155] 5% 1,3-dihydroxyanthraquinone soluble liquid, drug code Y5;

[0156] 4% 1,3-dihydroxyanthraquinone microemulsion, drug code R5;

[0157] 1% 1,3-dihydroxyanthraquinone aqueous solution, code name S5;

[0158] 5% 1,3,6-trihydroxy-2-methylanthraquinone soluble liquid, drug code Y6;

[0159] 4% 1,3,6-trihydroxy-2-methylanthraquinone microemulsion, drug code R6;

[0160] 1% 1,3,6-trihydroxy-2-methylanthraquinone aqueous solution, code name S6;

[0161] Table 6 Results of the protective effects of 18 antiviral agents on ordinary cigarettes

[0162]

[0163]

[0164] (2) Therapeutic effects on ordinary cigarettes

[0165] Common tobacco (Nicotiana tabacum) with uniform growth and robustness at the 5-6 leaf stage was selected for the test. The test set up two groups: the treatment group (i.e., three times of pesticide application after inoculation with TMV) and the control group (equal amount of clean water application after inoculation with TMV). The toxin source TMV was inoculated at a concentration of 1:20 (W / V). The pesticide was applied once every 5 days after inoculation, for a total of three times. The pesticide was 200 times diluted spray of 18 kinds of plant-derived antiviral agents, and 500 times diluted spray of the control pesticide morpholinoguanidine and copper acetate. The disease situation was checked at 14 days and 21 days after the last application of the pesticide, and the disease index and control effect were calculated. 60 tobacco seedlings were treated for each treatment, and the test was repeated 3 times. The control effect was calculated.

[0166] The results of the therapeutic effect determination are shown in Table 7.

[0167] Test reagents and codes are as follows (1);

[0168] Table 7 Results of the therapeutic effects of 18 antiviral agents on ordinary cigarettes

[0169]

[0170] The results of the potted plant test showed (Tables 6 and 7) that the 18 plant-derived antiviral agents showed good preventive and therapeutic effects on tobacco mosaic virus disease, and their protective and therapeutic effects were better than those of the control agents.

[0171] Example 21 Field plot efficacy test of 18 plant-derived antiviral agents against TMV

[0172] The plot test design is random arrangement, repeated 3 times, the plot area is about 30㎡ according to the actual situation, the selection of the test site requires uniform fertility, consistent crop planting and management level, and relatively uniform disease occurrence and damage degree; protection rows should be set up around each treatment room and the test area. Use 18 kinds of plant-derived antiviral agents 100, 200, and 400 times liquid for foliar spraying, and use 20% morpholinoguanidine. 500 times liquid copper ethyl wettable powder as the control agent for foliar spraying, and set up a water control; all test agents must be diluted twice. Start spraying from the early stage of the disease, and then spray once every 7 days, for a total of 3 times. Investigate the incidence rate and statistical disease index before the first spraying and 10 days after the last spraying, and calculate the prevention effect. The results are shown in Table 8.

[0173] The test reagents and codes are as follows:

[0174] 5% rubiacein soluble liquid, drug code Y1;

[0175] 4% rubiacein microemulsion, drug code R1;

[0176] 1% Rubia cordifolia aqueous solution, code name S1;

[0177] 5% rubiaceae lactone soluble liquid, drug code Y2;

[0178] 4% madder lactone microemulsion, drug code R2;

[0179] 1% madder lactone aqueous solution, code name S2;

[0180] 5% 2-methyl-1-hydroxyanthraquinone soluble liquid, drug code Y3;

[0181] 4% 2-methyl-1-hydroxyanthraquinone microemulsion, drug code R3;

[0182] 1% 2-methyl-1-hydroxyanthraquinone aqueous solution, code name S3;

[0183] 5% 2-methyl-1,4-dihydroxyanthraquinone soluble liquid, drug code Y4;

[0184] 4% 2-methyl-1,4-dihydroxyanthraquinone microemulsion, drug code R4;

[0185] 1% 2-methyl-1,4-dihydroxyanthraquinone aqueous solution, code number S4;

[0186] 5% 1,3-dihydroxyanthraquinone soluble liquid, drug code Y5;

[0187] 4% 1,3-dihydroxyanthraquinone microemulsion, drug code R5;

[0188] 1% 1,3-dihydroxyanthraquinone aqueous solution, code name S5;

[0189] 5% 1,3,6-trihydroxy-2-methylanthraquinone soluble liquid, drug code Y6;

[0190] 4% 1,3,6-trihydroxy-2-methylanthraquinone microemulsion, drug code R6;

[0191] 1% 1,3,6-trihydroxy-2-methylanthraquinone aqueous solution, code name S6;

[0192] Table 8 Field plot efficacy test of 18 antiviral agents against tobacco virus diseases

[0193]

[0194]

[0195]

[0196] Note: The data in the table are the average values ​​of 3 repetitions; in the "Protective Effect" column, different letters after the same number column indicate significant differences at the α=0.05 level.

[0197] From Table 8 above, it can be seen that among the 18 plant-based antiviral agents, the madder preparation has a good control effect on tobacco mosaic virus. When diluted 100, 200, and 400 times, it is significantly better than the control 20% morpholineguanidine. Ethyl copper wettable powder, and the difference in control effect is significant. The remaining preparations also have a certain control effect, which is equivalent to the control agent.

[0198] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the protection scope of the present invention.

Claims

1. Application of natural quinone compounds in the preparation of anti-plant virus agents, wherein the natural quinone compounds are madderol, and the mass percentage of the natural quinone compounds in the anti-plant virus agents is 1% to 5%; The plant virus is tobacco mosaic virus.

2. The use according to claim 1, characterized in that: The mass percentage of the natural quinone compounds in the anti-plant virus agent is 4%.

3. The use according to claim 1 or 2, characterized in that: The anti-plant virus agent is a microemulsion, a soluble liquid or an aqueous solution.

4. The use according to claim 3, characterized in that: The microemulsion is prepared from the following raw materials by weight percentage: Containing 1% to 5% of natural quinone compounds, 0% to 50% of organic solvents, 5% to 30% of surfactants, 5% to 10% of antifreeze agents, and the balance being water, the sum of the weight percentages of the raw materials being 100%; Endpoint values ​​of %0 are not included.

5. The use according to claim 3, characterized in that: The soluble liquid is prepared from the following raw materials in percentage by weight: Contains 1% to 5% of natural quinone compounds, 0% to 70% of organic solvents, 5% to 30% of surfactants, and the sum of the weight percentages of the raw materials is 100%; Endpoint values ​​of %0 are not included.

6. The use according to claim 3, characterized in that: The aqueous solution is prepared from the following raw materials in percentage by weight: Containing 1% to 5% of natural quinone compounds, 0% to 50% of organic solvents, 5% to 30% of surfactants, 5% to 10% of antifreeze agents, and the balance being water, the sum of the weight percentages of the raw materials being 100%; Endpoint values ​​of %0 are not included.

7. An anti-plant virus agent, characterized in that: It is made of natural quinone compounds as active ingredients and added with auxiliary agents. The preparation form is microemulsion, soluble liquid or aqueous solution; The natural quinone compound is madderol; The mass percentage of the natural quinone compounds in the anti-plant virus agent is 1% to 5%.

8. The anti-plant virus agent according to claim 7, characterized in that The mass percentage of the natural quinone compounds in the anti-plant virus agent is 4%.

Citation Information

Patent Citations

  • Plant virus resistant agent and preparation method thereof

    CN103749490A

  • Application of actinidia chinensis root-bark extract for preparing virucide for plants

    CN104738102A

  • Preparation method and application of novel anthraquinone compound with tobacco tobacco mosaic virus resistance activity

    CN106966888A

  • Preparation method and application of two anthraquinone compounds

    CN107011143A

  • Application of fennel extract in preparation of anti-plant-virus agent, and anti-plant-virus agent

    CN111657305A